VKTX

VKTX

USD

Viking Therapeutics Inc. Common Stock

$34.630-2.110 (-5.743%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$36.740

High

$38.000

Low

$34.615

Volume

3.77M

Company Fundamentals

Market Cap

3.9B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

6.60M

Exchange

NCM

Currency

USD

52-Week Range

Low $18.92Current $34.630High $70.41

Related News

Reuters

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera has become the obesity drug market's hottest ticket.

View more
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Analyst Upgrades

Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106

Canaccord Genuity analyst Edward Nash initiates coverage on Viking Therapeutics with a Buy rating and announces Price Target of $106.

View more
Canaccord Genuity Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $106
Analyst Upgrades

JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics with a Overweight and lowers the price target from $80 to $75.

View more
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $75
Analyst Upgrades

Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102

Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics with a Overweight and raises the price target from $98 to $102.

View more
Morgan Stanley Maintains Overweight on Viking Therapeutics, Raises Price Target to $102
PR Newswire

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...

View more
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...